(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -23.24%39.56B | 4.01%94.82B | 16.39%51.54B | -0.07%91.17B | -3.68%44.28B | 16.43%91.23B | 17.71%45.97B | -8.52%78.36B | -8.90%39.06B | 1.24%85.65B |
Operating income | -23.24%39.56B | 4.01%94.82B | 16.39%51.54B | -0.07%91.17B | -3.68%44.28B | 16.43%91.23B | 17.71%45.97B | -8.52%78.36B | -8.90%39.06B | 1.24%85.65B |
Cost of sales | 24.17%-24.52B | -4.73%-59.67B | -18.24%-32.34B | -1.83%-56.98B | 2.83%-27.35B | -16.92%-55.96B | -16.81%-28.14B | 11.09%-47.86B | 9.26%-24.09B | -0.17%-53.83B |
Operating expenses | 24.17%-24.52B | -4.73%-59.67B | -18.24%-32.34B | -1.83%-56.98B | 2.83%-27.35B | -16.92%-55.96B | -16.81%-28.14B | 11.09%-47.86B | 9.26%-24.09B | -0.17%-53.83B |
Gross profit | -21.68%15.04B | 2.81%35.15B | 13.42%19.21B | -3.08%34.19B | -5.01%16.94B | 15.66%35.27B | 19.17%17.83B | -4.16%30.5B | -8.30%14.96B | 3.09%31.82B |
Selling expenses | 37.45%-5.32B | 7.22%-14.99B | -8.15%-8.51B | 1.85%-16.15B | 2.47%-7.87B | -14.44%-16.46B | -19.53%-8.07B | 1.27%-14.38B | 5.77%-6.75B | -3.40%-14.57B |
Administrative expenses | -7.76%-4.32B | -14.18%-8.43B | -17.44%-4.01B | -4.78%-7.39B | -2.28%-3.41B | -8.85%-7.05B | -5.07%-3.34B | 1.34%-6.48B | -0.73%-3.17B | -3.66%-6.56B |
Profit from asset sales | ---- | --23.1B | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Revaluation surplus | 36.84%-840M | -453.09%-2.86B | -289.19%-1.33B | 141.95%810M | 127.97%703M | 56.32%-1.93B | 3.38%-2.51B | -218.59%-4.42B | -167.89%-2.6B | -80.76%3.73B |
-Changes in the fair value of investment property | 36.84%-840M | -453.09%-2.86B | -289.19%-1.33B | 141.95%810M | 127.97%703M | 56.32%-1.93B | 3.38%-2.51B | -218.59%-4.42B | -167.89%-2.6B | -80.76%3.73B |
Impairment and provision | ---- | -467.48%-925M | ---- | ---163M | ---- | ---- | ---- | ---- | ---- | ---- |
-Other impairment is provision | ---- | -467.48%-925M | ---- | ---163M | ---- | ---- | ---- | ---- | ---- | ---- |
Special items of operating profit | 234.63%381M | -181.25%-429M | -356.45%-283M | -76.64%528M | -108.72%-62M | -5.44%2.26B | 117.31%711M | 479.97%2.39B | -497.97%-4.11B | -159.34%-629M |
Operating profit | -2.64%4.95B | 158.91%30.62B | -19.34%5.08B | -2.24%11.83B | 36.15%6.3B | 58.95%12.1B | 376.95%4.63B | -44.82%7.61B | -115.37%-1.67B | -55.35%13.79B |
Financing income | 18.14%267M | 103.47%586M | 69.92%226M | -8.57%288M | -10.14%133M | -14.86%315M | -38.59%148M | -18.14%370M | 45.18%241M | 124.88%452M |
Financing cost | -8.03%-1.39B | -49.00%-2.61B | -57.23%-1.28B | 14.78%-1.75B | 24.44%-816M | 1.58%-2.06B | 4.93%-1.08B | 16.20%-2.09B | 10.62%-1.14B | 1.23%-2.49B |
Share of profits of associates | -15.69%1.47B | 207.79%3.56B | 171.18%1.75B | -16.52%-3.3B | 30.45%-2.45B | 71.24%-2.83B | 21.10%-3.53B | -1,212.99%-9.85B | -753.51%-4.47B | -33.16%885M |
Share of profit from joint venture company | 27.67%955M | -66.77%617M | -0.40%748M | -18.23%1.86B | -30.27%751M | 72.70%2.27B | 65.69%1.08B | -32.53%1.32B | -34.61%650M | -20.71%1.95B |
Earning before tax | -4.04%6.25B | 267.46%32.77B | 66.56%6.52B | -8.94%8.92B | 214.72%3.91B | 470.42%9.79B | 119.47%1.24B | -118.13%-2.64B | -155.82%-6.39B | -54.91%14.58B |
Tax | -1.52%-1.67B | 2.69%-2.93B | -23.98%-1.65B | 1.86%-3.01B | 13.30%-1.33B | -26.60%-3.07B | -46.10%-1.53B | 11.69%-2.43B | 35.94%-1.05B | 6.15%-2.75B |
After-tax profit from continuing operations | -5.92%4.58B | 405.30%29.84B | 88.50%4.87B | -12.18%5.91B | 987.29%2.58B | 232.65%6.72B | 96.09%-291M | -142.82%-5.07B | -175.87%-7.44B | -59.76%11.84B |
After-tax profit from non-continuing business | ---- | ---- | ---- | 122.69%364M | 278.81%447M | 68.09%-1.6B | --118M | ---5.03B | ---- | ---- |
Earning after tax | -5.92%4.58B | 375.96%29.84B | 60.68%4.87B | 22.44%6.27B | 1,850.87%3.03B | 150.72%5.12B | 97.67%-173M | -185.28%-10.1B | -175.87%-7.44B | -59.76%11.84B |
Minority shareholders should account for profits from continuing business | ---- | -52.39%985M | ---- | 17.02%2.07B | 77.32%1.11B | 91.34%1.77B | --626M | --924M | ---- | ---- |
Minority shareholders should account for non-continuing business profits | ---- | ---- | ---- | 200.00%5M | 171.43%5M | 75.00%-5M | ---7M | ---20M | ---- | ---- |
Minority profit | 2.94%665M | -52.51%985M | -42.06%646M | 17.64%2.07B | 80.13%1.12B | 95.02%1.76B | 104.97%619M | -68.07%904M | -83.77%302M | -51.11%2.83B |
Shareholders should account for profits from continuing business | ---- | 652.16%28.85B | ---- | -22.60%3.84B | 260.52%1.47B | 182.70%4.96B | ---917M | ---5.99B | ---- | ---- |
Shareholders should account for profits from non-continuing business | ---- | ---- | ---- | 122.45%359M | 253.60%442M | 68.06%-1.6B | --125M | ---5.01B | ---- | ---- |
Profit attributable to shareholders | -7.27%3.91B | 587.79%28.85B | 120.53%4.22B | 24.96%4.2B | 341.67%1.91B | 130.52%3.36B | 89.76%-792M | -222.12%-11B | -197.46%-7.74B | -61.88%9.01B |
Basic earnings per share | -5.17%0.55 | 612.50%3.99 | 123.08%0.58 | 24.44%0.56 | 336.36%0.26 | 130.82%0.45 | 89.32%-0.11 | -221.67%-1.46 | -197.17%-1.03 | -61.90%1.2 |
Diluted earnings per share | -5.17%0.55 | 612.50%3.99 | 123.08%0.58 | 24.44%0.56 | 336.36%0.26 | 130.82%0.45 | 89.32%-0.11 | -221.67%-1.46 | -197.17%-1.03 | -61.90%1.2 |
Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data